Oscar Health (NYSE:OSCR) Price Target Raised to $12.00

Oscar Health (NYSE:OSCR) had its price objective raised by equities researchers at UBS Group from $11.00 to $12.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “sell” rating on the stock. UBS Group’s price objective would indicate a potential downside of 32.21% from the stock’s current price.

A number of other research analysts also recently weighed in on the stock. Baird R W downgraded shares of Oscar Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 25th. Barclays reduced their price objective on Oscar Health from $17.00 to $11.00 and set an “underweight” rating for the company in a report on Wednesday, July 23rd. Weiss Ratings restated a “sell (d)” rating on shares of Oscar Health in a research note on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on Oscar Health in a research report on Tuesday, October 14th. They set a “neutral” rating and a $17.00 price target on the stock. Finally, Robert W. Baird reissued a “neutral” rating and issued a $14.00 price objective (down previously from $28.00) on shares of Oscar Health in a report on Friday, July 25th. Six research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $13.29.

Oscar Health Stock Up 6.9%

OSCR stock traded up $1.14 during trading on Friday, reaching $17.70. The stock had a trading volume of 24,633,435 shares, compared to its average volume of 14,423,208. Oscar Health has a one year low of $11.20 and a one year high of $23.80. The company’s 50 day moving average is $19.14 and its two-hundred day moving average is $16.74. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of -21.85 and a beta of 1.88. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR) last released its earnings results on Thursday, November 6th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02. The company had revenue of $2.93 billion for the quarter, compared to analysts’ expectations of $3.09 billion. Oscar Health had a negative return on equity of 13.78% and a negative net margin of 1.50%.The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) EPS. Oscar Health has set its FY 2025 guidance at EPS. Equities research analysts forecast that Oscar Health will post 0.69 EPS for the current year.

Insider Buying and Selling at Oscar Health

In other news, insider Mario Schlosser sold 395,000 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $18.43, for a total value of $7,279,850.00. Following the sale, the insider directly owned 501,148 shares of the company’s stock, valued at approximately $9,236,157.64. This represents a 44.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 24.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Oscar Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in Oscar Health by 23.8% in the 1st quarter. Victory Capital Management Inc. now owns 285,997 shares of the company’s stock worth $3,749,000 after buying an additional 54,938 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Oscar Health in the 1st quarter valued at $29,684,000. NewEdge Advisors LLC grew its holdings in shares of Oscar Health by 89.7% during the 1st quarter. NewEdge Advisors LLC now owns 188,058 shares of the company’s stock valued at $2,465,000 after purchasing an additional 88,946 shares during the last quarter. Matauro LLC bought a new stake in Oscar Health in the second quarter worth $1,508,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Oscar Health by 19.0% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 501,972 shares of the company’s stock worth $6,581,000 after purchasing an additional 79,979 shares during the last quarter. Institutional investors own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.